Highlights {#s1}
==========

1.  \- Naïve and effector CD4^+^ regulatory T cells have a reciprocal IL-17A--TNFα relationship; ~eff~Treg (TNF^low^/ IL-17A^high^) and ~naïve~Treg (TNF^high^/ IL-17A^low^).

2.  \- TNFα-TNF receptor-2 signaling regulates IL-17A expression via ubiquitin-editing *TNFAIP3*/A20 protein in ~eff~Treg.

3.  \- TNFα suppresses T-cell receptor and Janus kinase protein activity and promotes IL-17A expression in ~eff~Treg.

4.  \- siRNA-mediated *TNFAIP3* inhibition of ~eff~Treg, similar to TNFα signaling inhibition by anti-TNF treatment, leads to enhanced *IL17A* expression.

5.  \- TNFα signaling regulates the kinase architecture of antigen-activated ~eff~Treg.

Introduction {#s2}
============

Regulatory CD4^+^CD25^high^FOXP3^+^ T cells (Treg) are essential for human immune homeostasis ([@B1]). Human Treg cells reveal heterogeneity and contain multiple cell subsets that are characterized by differential expression of maturation, activation, and migration markers ([@B2]). At birth, the majority of the Treg are naïve ([@B3]), while later in life, the frequencies of CD45RA^−^ memory (effector) Treg increase at the expense of naïve Treg frequencies ([@B4]). Naïve (~naïve~Treg) and effector (~eff~Treg) Treg have distinct transcriptional, proteomic, metabolic, as well as enhancer and promoter landscapes ([@B5]--[@B7]).

Effector Treg cells were shown to express pro-inflammatory cytokines such as the autoimmune associated pro-inflammatory cytokine IL-17A, but also naïve Treg was found to produce IL-17A albeit at lower frequencies ([@B5], [@B8]). IL-17A-producing Treg have been observed in human inflammatory diseases such as psoriasis and IBD, suggesting that they contribute to the inflammatory process as has been demonstrated in mouse models ([@B9]--[@B14]). Although some cues that regulate IL-17A expression by Treg have been identified, including mTOR inhibition ([@B15]), CD28 superagonist stimulation ([@B16]), and platelet microparticle interaction ([@B17]), our mechanistic understanding of IL-17A expression by Treg is limited, let alone that this information is available for naïve and effector Treg. Recently, it has been elucidated that TNFR2 signaling is vital to establish Treg stability by promoting FOXP3 expression and inhibiting secretion of pro-inflammatory cytokines like IL-17A and IFNγ ([@B18], [@B19]). In conventional CD4+ memory T cells, inhibition of TNFR2 signaling by anti-TNF led to reduced expression of the anti-inflammatory regulator tumor necrosis factor-alpha-induced protein 3 (*TNFAIP3*, also known as A20), and as a consequence, this resulted in increased IL-17A expression ([@B20]). *TNFAIP3/*A20 acts as a ubiquitin-editing enzyme that regulates multiple other signaling pathways such as IL-17R ([@B21]) signaling and kinase activity \[e.g., PKC ([@B22]), TCR ([@B23]), and MAPK ([@B24])\].

TNF-TNFR2 signaling appears essential for human Treg expansion and proper function and additionally an autologous TNFα signaling feedback loop has been proposed that regulates IL-17A expression in human Treg ([@B18], [@B19], [@B25]--[@B29]). Anti-TNF therapy is successfully used for the treatment of severe chronic inflammatory diseases such as inflammatory bowel diseases, psoriasis, psoriatic arthritis, and rheumatoid arthritis ([@B30]--[@B33]). Paradoxically, it has been observed that in 0.6--5% of the patients treated with anti-TNF medication, this might unintentionally trigger specific forms of immune pathology, suggesting that inhibition of anti-TNF therapy affects Treg function ([@B34]--[@B37]). If and how naïve and effector Treg are affected by inhibition of TNFα is not known.

We hypothesize that TNFα signaling controls IL-17A expression in Treg by interfering at the level of kinase activity, which we here explored in ~eff~Treg. We demonstrate that inhibition of TNFα signaling by anti-TNF *in vitro* led to increased IL-17A expression. Down-regulation of the anti-inflammatory mediator *TNFAIP3* played a role in this process. Comprehensive kinome analysis revealed that inhibition of TNFα signaling in ~eff~Treg unexpectedly led to an increase of a kinase activity network containing TCR-linked kinases and immune signaling pathway such as the JAK. Small-molecule-based inhibition of these pathways prevented the anti-TNF-induced IL-17A expression in ~eff~Treg.

Results {#s3}
=======

~naïve~Treg and ~eff~Treg Cells Reveal a Reciprocal IL-17A---TNFα Relationship
------------------------------------------------------------------------------

To investigate the link between TNFα and IL-17A expression in naïve and effector Treg, FACS-sorted ~naïve~Treg (CD4^+^CD45RA^+^CD25^+^) and ~eff~Treg (CD4^+^CD45RA^−^CD25^high^) ([Figure 1A](#F1){ref-type="fig"}) derived from healthy volunteers were stimulated with PMA plus ionomycin, and subsequently *TNFA, IL17A, IL17F*, and *RORC* (RORɤt) expression was accessed by RT-qPCR ([Figure 1B](#F1){ref-type="fig"}). As compared to ~eff~Treg, ~naïve~Treg expressed significantly lower levels of *IL17A, IL17F, and RORC (p* = 0.0005, *p* = 0.0093, and *p* = 0.0016, respectively), while *TNFA* expression was higher (*p* = 0.0002) ([Figure 1B](#F1){ref-type="fig"}). Next, we compared the fold change in gene expression between the Treg subsets and observed a reciprocal gene expression signature for *TNFA, IL17A, IL17F*, and *RORC* ([Figure 1C](#F1){ref-type="fig"}). Correlation analysis revealed a reciprocal relationship between *TNFA* and *IL17A* (*r* = −0.50)*, IL17F* (*r* = −0.42), and *RORC* (*r* = −0.68) ([Figure 1D](#F1){ref-type="fig"}). As expected, a strong positive correlation between IL17A/IL17F (*r* = 0.81), IL17A/RORC (*r* = 0.74), and IL17A/RORC (*r* = 0.54) was observed. The inverse relationship was also confirmed at the protein level upon PMA plus ionomycin stimulation ([Figure 1E](#F1){ref-type="fig"}) or αCD3/CD28 stimulation of FACS-sorted Treg ([Figure 1F](#F1){ref-type="fig"}). As compared to ~eff~Treg, ~naïve~Treg hardly produced IL-17A, but showed an increased production of TNFα. Analysis of conventional T cells further supported the uniquely high production of IL-17A in these ~eff~Treg, as the numbers of IL-17A/FOXP3-positive cells in FACS-sorted naïve or memory CD4^+^CD25^−^ T cells were very low ([Figure S1](#SM1){ref-type="supplementary-material"}).

![Reciprocal TNFα and IL-17A expression in human ~naïve~Treg and ~eff~Treg cells. **(A)** An example of the FACS sorting strategy of ~naïve~Treg and ~eff~Treg based on CD4, CD45RA, and CD25 expression (I. dotplots), post-sorting analysis (II. dotplots) and confirmation of FOXP3 expression in the sorted cell population (III. histograms). Conventional CD4^+^CD45RA^−^CD25^−^ naïve T cells (T~naïve~), and CD4^+^CD45RA^−^CD25^−^ memory T cells (T~mem~) were sorted and displayed for comparison of FOXP3 expression levels (III). **(B)** RT-qPCR gene expression of *TNFA, IL17A, IL17F*, and *RORC* in ~naïve~Treg and ~eff~Treg after 20 h of PMA and ionomycin stimulation (*n* = 12). **(C)** Heatmap displaying the fold change of transcripts expression in ~eff~Treg within different donors (rows). ~naïve~Treg were used as reference to calculate the fold change. **(D)** Multiple correlation matrix depicting the correlation of gene expression in both Treg subsets (~naïve~Treg \[open dots\] and ~eff~Treg \[closed dots\]). Sample distribution (histogram) is shown, linear regression is also plotted (red lines), whereas *p*-value significance and *r-*values are displayed based on Pearson correlation test. *Y* and *X* axes depict the log10-fold change of *TNFA, IL17A, IL17F*, and *RORC* expression. Each column represents a gene; in every intersection (rows), we observe the correlation between genes. **(E)** Presence of the cytokines TNFα and IL-17A in culture supernatant after overnight stimulation of Treg subsets using PMA and ionomycin. Cytokines were measured using Luminex (*n* = 14). **(F)** Presence of TNFα and IL-17A in culture supernatants of αCD3/CD28/rhIL-2 activated Treg subsets after 5 days of culture (*n* = 3, mean ± SEM). For statistical analysis, Wilcoxon matched-pairs signed-ranks test **(B,E)**, or two-way ANOVA followed by a Bonferroni *post-hoc* test **(F)** were used. \**p* \< 0.05, \*\**p* \< 0.01,\*\*\**p* \< 0.001, ns, not significant.](fimmu-10-03047-g0001){#F1}

TNFα-TNF Receptor-2 Signaling Regulates IL-17A Expression via Ubiquitin-Editing *TNFAIP3*/A20 Protein in Effector CD4^+^ Regulatory T Cells
-------------------------------------------------------------------------------------------------------------------------------------------

Under the stimulation conditions mentioned above, ~eff~Treg, but not ~naïve~Treg, demonstrated a clear capacity to produce IL-17A; therefore, we focused our further experiments primarily on ~eff~Treg. To analyze if TNFα signaling regulates IL-17A expression in ~eff~Treg, FACS-sorted ~eff~Treg were stimulated with αCD3/CD28-beads plus rhIL-2 and supplemented with either soluble recombinant human (rh)TNFα or the anti-TNFα agent etanercept (ETN, here referred to as anti-TNF), which is a fusion protein of TNF receptor 2 and IgG1 Fc, which neutralizes TNFα and prevents TNFα signaling. Supplementation of rhTNFα as compared to supplementation of anti-TNF, resulted in a significant reduction of IL-17A expressing FOXP3+ ~eff~Treg (*p 3.19e-07*) ([Figure 2A](#F2){ref-type="fig"}). At the transcriptional level, we demonstrated that supplementation of rhTNFα suppressed IL-*17A*, IL-*17F*, and *RORC* gene expression in ~eff~Treg ([Figure 2B](#F2){ref-type="fig"}). These data support the idea that TNFα signaling controls IL-17A expression in ~eff~Treg.

![TNFα-TNFR2 signaling reduces IL-17A expression in activated ~eff~Treg, conceivably via the anti-inflammatory regulator *TNFAIP3/A20*. **(A)** Flow cytometry of intracellular IL-17A expression in FOXP3^high^ ~eff~Treg that were stimulated with αCD3/CD28/rhIL-2 for 5 days in the absence or presence of rhTNFα or anti-TNF (*n* = 15). **(B)** RT-qPCR gene expression of *IL-17A, IL-17F*, and *RORC*, **(C)** NFκB target genes *NFKB1, NFKB1A, NFKB2* (*n* = 5), and **(D)** *TNFAIP3* (*n* = 8) at day 4 of culture. **(E,F)** *TNFAIP3* and *IL-17A* gene expression of non-targeting-gene control (NTC) and *siTNFAIP3* ~eff~Treg after 6 days under αCD3/CD28/rhIL-2 stimulation (*n* = 3). **(G)** Histogram depicting the expression of TNFR1 and TNFR2 on ~eff~Treg directly after FACS sorting (*n* = 9). **(H)** Flow cytometry of IL-17A expression in FOXP3^high^ ~eff~Treg that were stimulated with αCD3/CD28 beads plus rhIL-2 with or without TNFR2 agonist for 5 days (*n* = 9). All data are shown as mean ± SEM. For statistical analysis, a Friedman test followed by Dunn\'s multiple comparison test **(A)**, a two-way ANOVA followed by a Bonferroni posttest **(B,C)**, and a Wilcoxon matched-pairs signed-rank test **(D,G,H)** were used. \**p* \< 0.05, \*\**p* \< 0.01,\*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001, ns, not significant.](fimmu-10-03047-g0002){#F2}

TNFα binding to its receptors (TNFR1 and TNFR2) leads to a cascade of intracellular events that culminate in NFκB translocation to the nucleus and subsequent transcription of NFκB target genes *NFKBIA* (encode Iκ*βα*), *NFKB1* (encode p50), and *NFKB2* (encode p52) ([@B38], [@B39]). Therefore, we analyzed the effect on the expression of NFκB target genes in ~eff~Treg after αCD3/CD28 stimulation with and without supplementation of rhTNFα or anti-TNF. Supplementation with rhTNFα led to a significant increase of *NFKBIA and NFKB2* expression, indicating that TNFα signaling promotes the expression of NFκB target genes, an indication of NFκB activation during Treg activation, while anti-TNF suppressed the NFκB pathway ([Figure 2C](#F2){ref-type="fig"}). We previously found that TNFα signaling enhanced *TNFAIP3* (tumor necrosis factor-induced protein 3) expression in conventional T cells ([@B20]). *TNFAIP3* encodes the ubiquitin-editing enzyme A20, which in turn regulates NFκB activity. Here, we also observed that TNFα signaling regulated *TNFAIP3* expression in ~eff~Treg ([Figure 2D](#F2){ref-type="fig"}). To demonstrate causality between suppression of *TNFAIP3* and enhanced expression of IL-17A, we carried out a small interfering RNA assay (siRNA) to inhibit *TNFAIP3* transcription. siRNA-mediated *TNFAIP3* inhibition of ~eff~Treg, similar to TNFα signaling inhibition by anti-TNF treatment, led to enhanced *IL-17A* gene expression ([Figures 2E,F](#F2){ref-type="fig"}).

As TNFα can bind to both TNFR1 and TNFR2, we measured the expression of these receptors on freshly isolated ~eff~Treg and demonstrated that they expressed TNFR2, but TNFR1 was hardly detected ([Figure 2G](#F2){ref-type="fig"}). The latter agrees with previous studies ([@B20], [@B40]) and suggests that TNFα-mediated regulation of IL-17A expression in ~eff~Treg might be primarily mediated via the TNFR2. To examine this, αCD3/CD28-stimulated ~eff~Treg were cultured in the absence and presence of a specific TNFR2 agonist for 5 days. TNFR2 agonist stimulation led to a reduction in the percentages of IL-17A expressing FOXP3+ cells ([Figure 2H](#F2){ref-type="fig"}). This indicates that IL-17A expression in ~eff~Treg subsets is regulated via TNFα-TNFR2 signaling. Together, these data suggest that TNFα signaling via TNFR2 promotes the expression of the anti-inflammatory mediator *TNFAIP3/*A20, which seems to prevent IL-17A expression in regulatory T cells, as ablation of TNFα signaling suppresses *TNFAIP3/*A20 and results in increased IL-17A expression in human Treg.

TNFα Suppresses T-Cell Receptor and Janus Kinase Protein Activity and Regulates IL-17A Expression in Effector Regulatory T Cells
--------------------------------------------------------------------------------------------------------------------------------

*TNFAIP3*/A20 has been demonstrated to regulate critical proteins involved in TCR ([@B23]), TNFα ([@B41]), IL-17R ([@B21]), and Wnt signaling ([@B20], [@B42]). Recently, we demonstrated that the prevention of TNFα signaling in conventional CD4^+^ memory T cells leads to inhibition of *TNFAIP3*/A20 expression, which subsequently leads to enhanced IL-17A expression ([@B20]). *TNFAIP3*/A20 has been shown to regulate kinase activity ([@B21], [@B23]). To better understand kinase regulation by TNFα signaling in ~eff~Treg, we here profiled the activity of \~300 kinases in FACS-sorted ~eff~Treg following stimulation with αCD3/CD28 beads in the absence or presence of anti-TNF or rhTNFα. Subsequently, we analyzed the threonine/serine and tyrosine kinase activity using a multiplex human kinase activity array. This kinome array employs \~300 peptide substrates with known phosphorylation sites and provides a reliable and high-throughput kinase profiling tool for further pathway elucidation (see *Materials and Methods*) ([@B43]). We found 30 unique and differentially activated kinases following anti-TNF vs. rhTNFα supplementation comparison ([Figure S2](#SM2){ref-type="supplementary-material"}). For the kinase activity profiling, we focused on the two most extreme states of TNF pathway signaling and addressed the differential kinase activity profile following ~eff~Treg activation following TNF vs. anti-TNF supplementation. The obtained kinome data were visualized using a volcano plot that shows the fold change of kinase activity and the associated level of significance (*p*-values) ([Figure 3A](#F3){ref-type="fig"}, left panel; raw data [Table S1](#SM4){ref-type="supplementary-material"}). We found that inhibition of TNFα signaling, as compared to the supplementation of rhTNFα, in activated ~eff~Treg significantly promoted the activity of multiple kinases (red symbols indicate *p* \< 0.05). The ranked log2-fold changes of kinase activity are shown in the right panel of [Figure 3A](#F3){ref-type="fig"}. Notably, several of the kinases were related to TCR signaling \[CD3ζ (CD247), CD3ε, ZAP70, and Lck\] ([@B44]). Also, cell cycle regulating (CALM, CD28, GSK3B, MAPK3, PGR, and JAK3) ([@B45], [@B46]) and apoptosis (ANXA2, Annexin V) ([@B47])-related kinases were induced.

![TNFα signaling in ~eff~Treg suppresses TCR and JAK kinase activity, leading to regulation of IL-17A expression. ~eff~Treg were stimulated with αCD3/CD28 beads and rh-IL-2 in the presence of rhTNFα or anti-TNF. On day 4, phosphoserine/threonine kinase (STK) and phosphotyrosine kinase (PTK) activity of cells were Analyzed using a kinome activity array. **(A)** Left panel: Volcano plot showing the fold change in kinase activity and adjusted *p*-values (red symbols, *p* \< 0.05; *n* = 4) in STK and PTK kinase activity. Right panel: Fold change in the kinases identified by comparing anti-TNF with rhTNFα conditions. Of note, TNFα was used as reference to calculate the fold change. Green texts indicate unique kinases that show increased activity upon comparison of anti-TNF to rhTNFα conditions; Blue texts represent kinases with enhanced activity upon comparison of comparing anti-TNF to the control (αCD3/CD28 stimulated without rhTNF or anti-TNF). **(B)** Cumulative STRING^©^ protein network analysis based on the identified kinases listed in **(A)**. **(C)** Flow cytometry of intracellular IL-17A expression in FOXP3^high^ ~eff~Treg. Pathway inhibition validation assays applying small chemical molecules in the stimulation assay as described above (mean ± SEM, *n* = 7). JAKi, JAK inhibitor (tofacitinib); Lcki, Lck inhibitor (A420983); PKCi, PKC inhibitor (AEB071); and p38i, p38MAPK inhibitor (UR13870). ANOVA Dunnett\'s testing **(A)** and Friedman test followed by Dunn\'s multiple comparisons test **(C)** were used. \**p* \< 0.05, \*\**p* \< 0.001, \*\*\**p* 0.0001, ns, not significant.](fimmu-10-03047-g0003){#F3}

To obtain a more comprehensive understanding of the kinase network and cellular pathways regulated by neutralization of TNFα, the kinases that were significantly activated following anti-TNF mAb treatment were analyzed using STRING (*Search Tool for the Retrieval of Interacting Genes/Proteins*). STRING is a web-based biological resource (<https://string-db.org>) of known and predicted protein--protein interactions enabling prediction of the functional protein association network of a group of given proteins by estimating the likelihood of meaningful biological interactions ([@B48]). In our analysis, we used the highest confidence interaction score (0.900) to associate all kinases that were significantly activated following anti-TNF treatment as listed in the right panel of [Figure 3A](#F3){ref-type="fig"}. STRING association analysis demonstrated that inhibition of TNFα signaling in activated ~eff~Treg involved prominent immune signaling pathways such as the PKC, p38-MAPK, and JAK pathways, which were all linked to TCR signaling \[CD3ζ (CD247) and CD3ε\] ([Figure 3B](#F3){ref-type="fig"}). Previously, these pathways were shown to be associated with the induction of IL-17A expression ([@B49]--[@B52]).

To validate if the predicted pathways were indeed involved in rhTNFα-induced suppression of IL-17A expression in ~eff~Treg, FACS-sorted ~eff~Treg were activated in the presence or absence of anti-TNF and specific kinase inhibitors of JAK/STAT (Tofacitinib), PKC (AEB071, Sotrastaurin), or p38 MAPK (UR13870). For the inhibition of TCR signaling, an Lck inhibitor (A420983) was applied. We demonstrated that suppression of JAK, and Lck kinases, but not PKC and p38, prevented the expression of IL-17A expression in ~eff~Treg that were activated under TNFα signaling inhibiting or not ([Figure 3C](#F3){ref-type="fig"}). In fact, suppression of JAK and Lck inhibited the expression of IL-17 similar to the TNF supplementation condition. The inhibitors tested did not affect FOXP3 expression ([Figure S3](#SM3){ref-type="supplementary-material"}).

Next, we performed a functional ontology enrichment analysis of the most significant biological process networks, processes, and diseases by submitting the kinase data that we identified in activated ~eff~Treg following supplementation vs. inhibition of TNFα to MetaCore™ database analysis. Significant enriched MetaCore™ GO process networks involved immune response-TCR signaling, cell cycle regulation, and lymphocyte proliferation ([Figure 4A](#F4){ref-type="fig"}). The most significantly enriched MetaCore™ Go processes based on the submitted kinases were kinase signaling pathways via transmembrane receptor protein tyrosine, signal transduction processes, and tyrosine phosphorylation and modification ([Figure 4B](#F4){ref-type="fig"}). Furthermore, there was an enrichment of cell communication and cell development processes. MetaCore™ Go diseases indicated a strong enrichment of autoimmune disease, next to other pathological conditions ranging from the nervous system, nutritional, and metabolic disorders ([Figure 4C](#F4){ref-type="fig"}). Together, these data demonstrated that CD3 and CD28 activation of ~eff~Treg in the absence of TNF-signaling by anti-TNF treatment promotes tyrosine kinase activity of relevant TCR-associated signaling pathways.

![Enrichment analysis of the kinome array data. Functional ontology enrichment analysis using the MetaCore™ database reveals **(A)** the distinct biological networks, **(B)** the different biological processes, and **(C)** various diseases related to kinases identified in [Figure 3](#F3){ref-type="fig"}. The probability of a random intersection between the set of kinases with ontology entities was estimated with the "*p*" value of the hypergeometric intersection. A lower "*p*" value means higher relevance of the entity to the dataset, which appears in higher rating for the entity.](fimmu-10-03047-g0004){#F4}

Discussion {#s4}
==========

Human Treg can express the pro-inflammatory cytokine IL-17A under specific conditions; a phenomenon referred to as Treg plasticity ([@B5], [@B8]). The molecular mechanisms regulating this phenomenon are not well-understood. In our current work, we demonstrate that TNFα signaling regulates IL-17A expression in ~eff~Treg by controlling a kinase activity network that includes TCR linked kinases and other prominent immune signaling kinase pathways such as the JAK pathway. Also, TNFα-mediated regulation of the anti-inflammatory mediator *TNFAIP3*/A20 appeared crucial to control IL-17A expression by ~eff~Treg. TNFR2 is the main receptor for TNFα signaling in Treg. TNFR2 stimulation has been demonstrated to support Treg stability ([@B18], [@B19], [@B25], [@B53]), whereas the effect of TNF signaling on the stability of Treg is ambiguous ([@B54], [@B55]). Here, we show that TNFR2 is highly expressed on human ~eff~Treg, and TNF-TNFR2 signaling in ~eff~Treg acts as a negative regulator of IL-17A expression by controlling TCR and JAK signaling.

STRING association analysis revealed that inhibition of TNFα signaling is associated with increased TCR associated signaling of CD3ζ, CD3ε, ZAP70, and Lck, indicating that TNFα signaling in ~eff~Treg functions as a rheostat of TCR signal transmission. Although information of TNFα stimulation on the TCR signaling in Treg is lacking, it has been shown in CD4+ T cells of both mice and man that TNFα stimulation results in specific down-regulation of TCRζ expression and impaired TCR/CD3 signaling, including phosphorylation of the TCRζ, CD3ε, ZAP-70 tyrosine kinase, and linker for activation of T cells (LAT) ([@B56]). TCR signaling is essential for both effector and regulatory T cells ([@B57]). Treg have a more extensive TCR repertoire than effector T cells, and TCR signaling is crucial for proper Treg function ([@B58]--[@B61]). Signaling via the T cell antigen receptor of Treg is critical for FOXP3 expression and their suppressive activity. Mutations resulting in signaling-deficient TCRζ chains led to increased Treg numbers with higher suppressive activity ([@B62]--[@B64]). Reduced TCR signaling will alleviate downstream signaling and favor Treg cell lineage commitment. TNFα signaling, as we demonstrate here, seems to safeguard TCR-related kinase activity in ~eff~Treg and stabilize Treg function as illustrated by preventing IL-17A expression. Note that anti-TNF had a mild effect on the induction of IL-17A expression in ~eff~Treg, which is in contrast to its clear induction of IL-17A in conventional memory T cells ([@B20]). This phenomenon may be caused by the poor intrinsic capacity of ~eff~Treg to produce TNFα *in vitro*. In fact, highly pure FACS-sorted ~eff~Treg barely produced TNFα (41.35 pg/ml ± 6.75), whereas memory conventional T cells produced significantly higher levels (335.7 pg/ml ± 65.33, *n* = 4) (data not shown).

Next to TCR-derived signals, Treg integrates inputs from cytokine, chemotactic, and metabolic cues to fulfill their function optimally. Proximal cytokine signaling often takes place via JAK-STAT signaling ([@B65]). *IL-17A* gene transcription is associated with JAK-STAT3 signaling ([@B66]). Inhibition of TNFα signaling using anti-TNF inhibitor ETN was associated with increased JAK1 and JAK3 kinase activity in αCD3/CD28 stimulated ~eff~Treg. Inhibition of JAK1 and JAK3 kinase activity by the clinically applied JAK inhibitor tofacitinib prevented IL-17A expression in anti-TNF-treated ~eff~Treg, suggesting that TNFα signaling is involved in driving JAK/STAT signaling. Although TNFα is not a prototypic JAK/STAT activating cytokine, the anti-inflammatory molecule A20 (encoded by *TNFAIP3*) that is a downstream target of TNFα signaling acts as a regulator of STAT ([@B67], [@B68]). The absence of A20 in myeloid cells resulted in enhanced STAT1-dependent inflammation ([@B68]). This relationship needs to be confirmed in ~eff~Treg.

Although anti-TNF therapy is improving the life quality of many patients with chronic inflammatory diseases, 10--20% of patients do not respond to the treatment while 0.6--5% of patients treated with TNF inhibitors reveal paradoxical immune-mediated inflammatory side effects ([@B36], [@B37]). Although the mechanism of the latter phenomenon is not fully understood, it might be of interest to consider an additional JAK inhibitor treatment such as tofacitinib or other JAK inhibitors to prevent the putative IL-17A expression by Treg. Also, regarding Treg-based immune therapy in transplantation or autoimmunity, the clinical design has started to consider strategies to minimize the risks of Treg plasticity ([@B69]) at the time of ex vivo production and following *in vivo* administration ([@B70], [@B71]). Our results suggests that TNFα-TNFR2 signaling or inhibition of JAK signaling might favor Treg stability. Along with this line of reasoning, it has been demonstrated that JAK inhibition ([@B72]) as well as TNFR2 stimulation ([@B18], [@B19]) support human Treg function and prevent Treg plasticity.

In conclusion, we demonstrated an inverse production of TNFα and IL-17A between human naïve and effector Treg cells. Supplementation of rhTNFα led to a down-regulation in the frequency of IL-17A-producing ~eff~Treg, mainly via the activation of NFkB pathway as well as the up-regulation of *TNFAIP3/A20* expression. TNFR2 receptor seems to play a crucial role since we hardly detected any expression of TNFR1 on ~eff~Treg and treatment of ~eff~Treg with TNFR2 specific agonist resulted in a similar inhibition of IL-17A production. Accordingly, inhibition of TNFα signaling using the clinically applied anti-TNF inhibitor ETN led to decreased *TNFAIP3* and increased *IL-17A* expression, a phenomenon similar to what is observed in human conventional memory CD4+ T cells. Kinome activity screening of αCD3/CD28 stimulated ~eff~Treg revealed that anti-TNF led to an increase in kinase activity of multiple kinases including CD3ζ (CD247) and LcK. A functional ontology enrichment analysis indicated that these kinases were highly associated with different immune response signaling pathways including TCR-, JAK-mediated pathways. We propose that these findings might be relevant for optimizing anti-TNF-based therapy and may aid in preventing Treg plasticity in case of Treg-based cell therapy.

Materials and Methods {#s5}
=====================

Study Approval
--------------

The protocols of this study were performed in agreement with the Declaration of Helsinki and in accordance with the Radboud university medical center (Radboudumc) in Nijmegen, the Netherlands.

Subjects
--------

Blood buffy coats from voluntary donors were purchased from the Sanquin Blood Bank, Nijmegen, the Netherlands. The volunteers gave written informed consent.

Regulatory T Cell Isolation
---------------------------

CD4^+^ T cells were isolated using RosetteSep™ Human CD4^+^ T cell enrichment cocktail 25--50 μl of cocktail/ml of blood (StemCell Technologies, Vancouver, Canada) according to the instructions of the supplier. To sort CD4^+^CD25^+^CD45RA^+^ (~naïve~Treg) and CD4^+^CD25^high^CD45RA^−^ (~eff~Treg), the purified CD4^+^ cells were washed and stained with anti-CD25-BV510 (*M-A251*, BD, New Jersey, USA), anti-CD45RA^−^ PE (*4KB5*, Dako, Brüsseler Straße, Germany), CD4-PE-Cy5.5 (*13B8.2*, Beckman-Coulter, California, United States), and FACS-sorted on a FACSAria™ III machine (BD Biosciences, New Jersey, United States). The gating strategy during FACS sorting, post-sorting purity analysis, and confirmation of FOXP3 expression in freshly sorted cell subsets are described in [Figure 1A](#F1){ref-type="fig"}. The purity of the sorted cell populations was 95.3 ± 4.1% (mean ± SD).

Cell Culture
------------

RPMI-1640 Dutch modified (Gibco, Massachusetts, United States) culture medium, containing sodium bicarbonate and 20 mM HEPES, supplemented with penicillin/streptomycin (100 U/ml), sodium pyruvate (1 mM), glutamine/glutamax, and 10% human pooled serum (HPS, Radboudumc), was used in all experiments. After cell isolation, 2.5 × 10^4^ cells/well were cultured in 96-well U-bottom plates and stimulated with Dynabeads^®^ Human T-Activator CD3/CD28 (αCD3/CD28 beads, 1:5 of bead:cell ratio) (Gibco, Massachusetts, United States) in the presence of recombinant human (rh) IL-2 (rhIL-2, 100 U/ml) (Proleukin Prometheus Laboratories, California, United States). In some conditions, cultures were supplemented with rhTNFα (50 ng/ml, R&D, Minnesota, United States), or TNFα inhibitors etanercept (5 μg/ml; ETN---Enbrel, Pfizer, New York, United States), or TNFR2 agonist (2.5 μg/ml, Clone *MR2-1*, Hycult Biotech, Uden, the Netherlands). To examine the effect of a pharmaceutical inhibitor, tofacitinib (0.112 μM, Pfizer, New York, United States), PKC inhibitor Sotrastaurin (1 μM), Lck inhibitor A420983 (1 μM), or p38α/β kinase inhibitor UR13870 (10 μM) was pre-incubated with the FACS-sorted cells for 30 min before the addition of any stimulus. In some cases, cells were stimulated with PMA (12.5 ng/ml) and ionomycin (500 ng/ml) for 20 h.

Flow Cytometry
--------------

Flow cytometry was performed using a 10-color Navios Flow cytometer (Beckman Coulter, California, United States), which is equipped with blue (488 nm), red (638 nm), and violet (405 nm) lasers. For surface staining, the following antibodies were used: anti-CD3-ECD (*UCHT1*), anti-CD45RA-ECD (*2H4LDH11LDB9*), anti-CD45-KO (*J33*), anti-CD4-PE-Cy5.5 (*13B8.2)*, and anti-CD8-APC-AF700 (*B9.11*) (all from Beckman-Coulter); anti-TNFR1-AF488 (*16803*, R&D); and anti-TNFR2-APC (*22235*, R&D). For intracellular staining, the following antibodies were used: anti-IFNγ-PE-Cy7 (*4S.B3*) and anti-IL-17A-AF-660 (*eBio64DEC17*) (eBioscience, California, United States). Unstained (Fluorescence Minus One, FMO) samples were also measured to help set the gates during data analysis. To evaluate cytokine production, we challenged the cultured Treg subsets for another 4 h with PMA (12.5 ng/ml), ionomycin (500 ng/ml), and Brefeldin A (5 μg/ml) (Sigma-Aldrich, Missouri, United States) before performing the FACS staining process. Briefly, cells were stained with the fixable viability dye-eFluo 780 (FVD, eBioscience) for 30 min at 4°C, following with surface mAb staining, cell fixation, and permeabilization by using the Intracellular Fixation & Permeabilization Buffer Set (eBioscience) and intracellular mAb staining. For flow cytometry data analysis, Kaluza1.5 software (Beckman Coulter) was used.

Small Interfering RNA Transfection
----------------------------------

For small interfering RNA (siRNA) knockdown of *TNFAIP3*, Accell SMARTpool siRNA (Dharmacon, Colorado, United States) was used according to the manufacturer\'s instructions. Briefly, 1 × 10^5^ ~eff~Treg cells per well were stimulated with αCD3/CD28 beads (1:5 of bead:cell ratio) in Accell Delivery Medium (Dharmacon) supplemented with rhIL-2 (100 U/ml) and incubated with 1 mmol cyclophilin B siRNA (positive control), or 1 mmol non-targeting control siRNA, or 1 mmol *TNFAIP3* siRNA for 120 h (for siRNA sequences, see [Table S2](#SM5){ref-type="supplementary-material"}). Quantitative real-time PCR (RT-qPCR) was performed to confirm the knockdown of the target gene expression.

RT-qPCR
-------

Total RNA was extracted by using the RNeasy Plus Micro Kit (Qiagen) followed by cDNA synthesis using the SuperScript III First-Strand Synthesis System and Oligo(dT)20 primer (Thermo Fisher Scientific, Massachusetts, United States). TaqMan gene expression assays were purchased from Thermo Fisher Scientific ([Table S3](#SM6){ref-type="supplementary-material"}). RT-PCR was acquired in a 7500 Real-Time PCR System (Applied Biosystems). RT-qPCR cycle values (C~T~) obtained for specific mRNA expression in each sample were normalized to the C~T~ values of human *HPRT1* (endogenous control), resulting in ΔC~T~ values (log ratio of the gene concentrations) that were used to calculate the relative gene expression.
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Then, we performed an exponential conversion of ΔC~T~, namely, 2^−ΔCT^ using the following formula:
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2^−ΔCT^ representing the relative gene expression was used in [Figures 1B,E,F](#F1){ref-type="fig"}.

~eff~Treg stimulated in the absence of anti-TNF or rhTNFα were used as a baseline to calculate the relative gene expression in fold change (ΔΔC~T~) for ~eff~Treg stimulated in the presence of rhTNFα *vs*. ETN treatment.
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Subsequently, we performed an exponential conversion of *ΔΔC*~T~, namely, 2^−ΔΔCT^ using the following formula:
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2^−ΔΔCT^ representing the relative gene expression in fold change was employed for [Figures 2B--D](#F2){ref-type="fig"}. In [Figures 1C,D](#F1){ref-type="fig"}, log10 ΔΔC~T~ was employed. The Relative Quantification app (Thermo Fisher Scientific cloud) was used for data analysis.

Measurement of Cytokines Secretion
----------------------------------

The cell culture supernatants were analyzed for the presence of IL-17A, IFNγ, and TNFα using Bio-Plex Pro Human Th17 Cytokine Assays (Bio-Rad, California, United States) according to the manufacturer\'s instruction. The cytokine concentrations were measured using a Luminex^100^ machine (Luminex Corp., Texas, United States). The lowest limit of detection was \<1.870 pg/ml for IL-17A, \<2.411 pg/ml for IFNγ, and \<2.231 pg/ml for TNFα.

Protein Kinase Chip Assay
-------------------------

After sorting and stimulations of cells, samples were frozen for further analysis. The protein isolation was performed according to the manufacturer\'s instruction (P1160, PamGene International B.V., \'s-Hertogenbosch, the Netherlands). Kinase activity was measured with PamGene\'s Protein Tyrosine Kinase (PTK) PamChip (Cat. number 86402) and Serine Threonine kinase (STK) PamChip (Cat. number 87102). Each PTK PamChip array contains 196 peptides immobilized on a porous membrane, whereas each STK PamChip array contains 144 peptides (see the full list of peptides at [www.pamgene.com](http://www.pamgene.com)). The peptide sequences (13 amino acids long) harbor phosphorylation sites, defined based on literature or derived from computational predictions and are correlated with one or multiple upstream kinases. A fluorescently labeled anti-phospho-Tyr antibody (PY20) is used to detect the phosphorylation activity of tyrosine kinases present in the sample. For the STK assay, an antibody mix is used to detect the phosphorylated Ser/Thr, and the 2nd FITC-conjugated antibody is used in a detection mix to quantify the phosphorylation signal. BioNavigator software 6.3 (PamGene) was used to determine signal intensities, peptide quality control (QC) and preselection (phosphorylation kinetics, or increase in signal over time, in 25% of the arrays analyzed), Log 2 transformation, ANOVA-Dunnett\'s testing, and data visualization. Mapping and pathway elucidation analysis were performed using METACORE™ (Clarivate Analytics, PA, USA) and STRING ([@B73]). As described by the GeneGo manufacturer\'s report, the analysis consists in matching the protein IDs of possible targets for the "common," "similar," and "unique" sets with protein IDs in functional ontologies in MetaCore ([@B73]). The lower *p*-value means a higher relevance of the entity to the dataset, which shows a higher rating for the entity.

Statistics
----------

Statistical analysis was performed using GraphPad Prism 5.0 for Windows (GraphPad Software, San Diego, California, USA) and R. For experiments with more than two groups of matched samples, we used non-parametric Friedman test followed by Dunn\'s Multiple Comparison Test, whereas for experiments with only two groups of matched samples, we employed non-parametric Wilcoxon matched-pairs signed-rank test.
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###### 

Expression of IL-17A in Conventional and regulatory T cells. Sorted naïve T cells (CD4^+^CD45RA^+^CD25^−^), memory T cells (CD4+CD45RA^−^CD25^−^), naïve Treg (CD4^+^CD45RA^+^CD25^low^) and effector Treg (CD4+CD45RA^−^CD25^high^) were stimulated with anti-CD3/CD28 bead plus rhIL-2. Cells were harvested on day 5 and intracellular FOXP3 and IL-17A expression were detected by FACS staining.
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Click here for additional data file.

###### 

Kinome data analysis. Kinase activity of ~eff~Treg following αCD3/CD28 bead plus rhIL-2 activation in the absence or presence of anti-TNF or rhTNFα. Significant changes of kinase activities are presented in a Venn diagram (**A**, left panel) and a bar plot that ranked based on the log2 fold-change of kinase activities. **(B,C)** Bar graphs showing significant changes of kinase activity between anti-TNF and αCD3/CD28 control **(B)** or rhTNF and αCD3/CD28 control **(C)**.
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###### 

The Janus kinase, Lck, PKC and p38 MAPK inhibitors do not affect FOXP3 expression in ~eff~Treg. ~eff~Treg were stimulated with αCD3/CD28 beads in the presence or absence of rhTNFα or anti-TNF or small chemical molecules such as JAK inhibitor (tofacitinib), Lck inhibitor (A420983), PKC inhibitor (AEB071) and p38MAPK inhibitor (UR13870) for 5 days. Flow cytometry analysis of intracellular FOXP3 expression (*n* = 5). Data are shown as mean ± SEM.
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###### 

Kinome Log 2-transformed dataset.
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###### 

Target genes used for siRNA interference.
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Primers used for RT-qPCR.
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